AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total ... Read More on AZN: AstraZeneca NewsMORE Related Stocks ...

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

AstraZeneca CEO Pascal Soriot received a total compensation ... Moderna’s latest earnings report produced a beat on Q4 2024 revenue but the drugmaker lost more than expected for the period. The ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...

Since we last reported in November 2024, AstraZeneca has initiated two Phase III trials evaluating rilvegostomig combinations versus standard of care with one trial in first-line squamous non ...

Revenue: $1.5 million for Q4 2024; $27.9 million for the full year ... targeting a less competitive landscape. AstraZeneca's initiation of seven Phase 3 trials with rilvegostomig, derived from ...